OSMAC-Based Discovery and Biosynthetic Gene Clusters Analysis of Secondary Metabolites from Marine-Derived Streptomyces globisporus SCSIO LCY30
-
Published:2023-12-28
Issue:1
Volume:22
Page:21
-
ISSN:1660-3397
-
Container-title:Marine Drugs
-
language:en
-
Short-container-title:Marine Drugs
Author:
Li Yanqing123, Gong Naying4, Zhou Le13, Yang Zhijie123, Zhang Hua4, Gu Yucheng5ORCID, Ma Junying123ORCID, Ju Jianhua123ORCID
Affiliation:
1. CAS Key Laboratory of Tropical Marine Bio-Resources and Ecology, RNAM Center for Marine Microbiology, Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China 2. University of Chinese Academy of Sciences, Beijing 110039, China 3. Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou), Guangzhou 511458, China 4. Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Institute of Laboratory Medicine, Guangdong Medical University, Dongguan 523808, China 5. Syngenta Jealott’s Hill International Research Centre, Bracknell RG42 6EY, Berkshire, UK
Abstract
The one strain many compounds (OSMAC) strategy is an effective method for activating silent gene clusters by cultivating microorganisms under various conditions. The whole genome sequence of the marine-derived strain Streptomyces globisporus SCSIO LCY30 revealed that it contains 30 biosynthetic gene clusters (BGCs). By using the OSMAC strategy, three types of secondary metabolites were activated and identified, including three angucyclines, mayamycin A (1), mayamycin B (2), and rabolemycin (3); two streptophenazines (streptophenazin O (4) and M (5)); and a macrolide dimeric dinactin (6), respectively. The biosynthetic pathways of the secondary metabolites in these three families were proposed based on the gene function prediction and structural information. The bioactivity assays showed that angucycline compounds 1–3 exhibited potent antitumor activities against 11 human cancer cell lines and antibacterial activities against a series of Gram-positive bacteria. Mayamycin (1) selectively exhibited potent cytotoxicity activity against triple-negative breast cancer (TNBC) cell lines such as MDA-MB-231, MDA-MB-468, and Bt-549, with IC50 values of 0.60–2.22 μM.
Funder
Fundamental Research & Applied Fundamental Research Major Project of Guangdong Province Key Science and Technology Project of Hainan Province National Natural Science Foundation of China Local Innovation and Entrepreneurship Team Project of Guangdong Open Program of Shen Zhen Bay Laboratory Nansha District Science and Technology Plan Project Rising Star Foundation of the South China Sea Institute of Oceanology
Subject
Drug Discovery,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Pharmaceutical Science
Reference48 articles.
1. Marine actinomycetes-derived natural products;Yang;Curr. Top. Med. Chem.,2019 2. Ser, H.L., Tan, L.T., Law, J.W., Chan, K.G., Duangjai, A., Saokaew, S., Pusparajah, P., Ab Mutalib, N.S., Khan, T.M., and Goh, B.H. (2017). Focused review: Cytotoxic and antioxidant potentials of mangrove-derived Streptomyces. Front. Microbiol., 8. 3. Julianti, E., Abrian, I.A., Wibowo, M.S., Azhari, M., Tsurayya, N., Izzati, F., Juanssilfero, A.B., Bayu, A., Rahmawati, S.I., and Putra, M.Y. (2022). Secondary metabolites from marine-derived fungi and actinobacteria as potential sources of novel colorectal cancer drugs. Mar. Drugs, 20. 4. Novel antibiotic screening methods to awaken silent or cryptic secondary metabolic pathways in actinomycetes;Onaka;J. Antibiot.,2017 5. Bode, H.B., Bethe, B., Höfs, R., and Zeeck, A. (2002). Big effects from small changes: Possible ways to explore nature’s chemical diversity. ChemBioChem, 3.
|
|